Simultaneous Measurement Of Cancer Specific Quality Of Life And General Health Status In Gynecologic Malignancies
Oncology
Gil K M; Von Gruenigen V E; Frasure H E; Grandon M; Hopkins M P; Jenison E L
Journal of Clinical Oncology
2004
2004-07
Journal Article or Conference Abstract Publication
n/a
Body Weight And Composition Changes In Ovarian Cancer Patients During Adjuvant Chemotherapy
body composition; breast cancer; chemotherapy; gain; Obstetrics & Gynecology; Oncology; ovarian cancer; weight; women
Gil K M; Frasure H E; Hopkins M P; Jenison E L; Von Gruenigen V E
Gynecologic Oncology
2006
2006-10
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1016/j.ygyno.2006.03.005" target="_blank" rel="noreferrer noopener">10.1016/j.ygyno.2006.03.005</a>
Patient Characteristics Influencing Quality Of Life In Gynecologic Cancer
Oncology
Gil K; Frasure H E; Jenison E; Hopkins M; Von Gruenigen V E
Journal of Clinical Oncology
2006
2006-06
Journal Article or Conference Abstract Publication
n/a
The in vitro antitumor activity of vitamins C and K-3 against ovarian carcinoma
alternative medicine use; aspects; autoschizis; cancer-chemotherapy; cell-lines; double-blind; k-3 combinations; mitomycin-c; Oncology; ovarian-cancer; phase-ii trial; pretreatment; tumor; ultrastructural; vitamin C; vitamin K-3
Background: The objective was to evaluate the cytotoxic effect and mechanism of action of vitamins C (VC) and K-3 (VK3) on ovarian carcinoma. Materials and Methods: Cytotoxicity assays were performed on ovarian cancer cell lines with VC, VK3 or a VC/VK3 combination. FIC index was employed to evaluate synergism. Flow cytometry was accomplished at 90% cytotoxic doses. Light, transmission electron microscopy and DNA isolation were performed. Results: Antitumor activity was exhibited by both VC, VK3 and VC/VK3. VC/VK3 demonstrated synergistic activity. VC/VK3 may induce a G(1) block in the cell cycle. Combined vitamin treatment resulted in cells that maintain apparently intact nuclei while extruding pieces of organelle-free cytoplasm. Degradation of chromosomal DNA was observed. Conclusion: Cell death (autoschizis) displayed characteristics of both apoptosis and necrosis. The cytotoxic effects observed may enable vitamins C and K-3 to play an adjuvant role in the treatment of ovarian cancer.
Von Gruenigen V E; Jamison J M; Gilloteaux J; Lorimer H E; Summers M; Pollard R R; Gwin C A; Summers J L
Anticancer Research
2003
2003-07
Journal Article
n/a
Surgical treatments for vulvar and vaginal dysplasia - A randomized controlled trial
aspiration; carbon-dioxide laser; carcinoma; excision; imiquimod cream; intraepithelial neoplasia-iii; management; Obstetrics & Gynecology; therapy; vaginectomy; vaporization
OBJECTIVE: To compare pain, adverse effects and recurrence of dysplasia in patients with vaginal intraepithelial neoplasia or vulvar intraepithelial neoplasia prospectively treated by carbon dioxide laser or ultrasonic surgical aspiration. METHODS: Patients were randomly assigned to receive treatment by laser or ultrasonic surgical aspiration from 2000-2005. Preoperative biopsy was done to confirm presence of dysplasia. Patients completed a visual analog scale regarding pain and were evaluated at 2-4 weeks to assess scarring, wound healing, and adverse effects. Patients returned every 3 months for 1 year for pelvic examination and cytology to assess recurrence. Follow-up colposcopy and biopsy were used at the discretion of the treating physician. Student t test, X-2, analysis of variance and multiple logistic regression were used for analysis. RESULTS: One hundred ten patients were randomly assigned. Ninety-six (87.3%) patients completed 1 year follow-up. Mean age of patients was 48.5 years. Mean visual analog scale score was significantly lower in patients treated by ultrasonic surgical aspiration (20.7 compared with 35.1; P=.032). For patients with vulvar lesions, there was less scarring with ultrasonic surgical aspiration (P<.01). Recurrence overall was 25% and was similar for ultrasonic surgical aspiration compared with laser (relative risk 0.96, 95% confidence interval 0.64-1.50, number needed to treat 95.6). Recurrence was associated with younger age (P<.01). CONCLUSION: Patients treated with ultrasonic surgical aspiration for vulvar and vaginal dysplasia reported less postoperative pain. Vulvar scarring was more common in patients treated by the laser. There was no difference in recurrence of dysplasia during a 1-year follow-up period between the two surgical modalities. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www. clinicaltrials.gov, NCT00394758.
Von Gruenigen V E; Gibbons H E; Gibbins K; Jenison E L; Hopkins M P
Obstetrics and Gynecology
2007
2007-04
Journal Article
<a href="http://doi.org/10.1097/01.AOG.0000258783.49564.5c" target="_blank" rel="noreferrer noopener">10.1097/01.AOG.0000258783.49564.5c</a>
Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: The roles of surgery and chemotherapy
alternative medicine use; behaviors; breast-cancer; chemotherapy; complementary and alternative medicine; complementary/alternative; energy-balance; functional assessment; gynecologic; medicine; Obstetrics & Gynecology; Oncology; Oncology; ovarian-cancer; quality-of-life; receiving adjuvant chemotherapy; Surgery; trial; women
Objectives. To prospectively evaluate quality of life (QoL), use of complementary and alternative medicine (CAM), and diet/exercise changes in ovarian cancer patients during the first 6 months following diagnosis. Methods. Patients with newly diagnosed ovarian cancer were enrolled pre- or post-operatively and surveyed at 3 and 6 months. The Functional Assessment of Cancer Therapy (FACT-G), Medical Outcomes Survey (SF-36), and CAM/diet/exercise questionnaires were used. Independent samples t test and repeated measures ANOVA were used. Results. Forty-two patients underwent surgical debulking and staging prior to chemotherapy. Patients completing the initial surveys post-operatively had significantly lower physical FACT-G and SF-36 physical scores compared to patients completing the surveys pre-operatively. In patients completing the baseline survey pre-operatively, there was a decrease in physical scores at 3 months (after surgery and during chemotherapy). There was no change observed at 3 months relative to baseline when patients completed the baseline survey post-operatively. Increases in physical and functional well-being were seen at 6 months relative to 3 months. There were no changes in emotional or social scores over time. CAM use increased over time; main reasons were to improve QoL and relieve symptoms. Alterations in diet and exercise were not seen. Conclusions. These data highlight the need to conduct assessments before and after surgery to identify effects due to surgery and/or chemotherapy. Patients may be using CAM during chemotherapy to deal with symptoms and compensate for decreased QoL. Intervention trials should be implemented to increase QoL following surgery and during adjuvant chemotherapy. (c) 2006 Elsevier Inc. All rights reserved.
Von Gruenigen V E; Frasure H E; Jenison E L; Hopkins M P; Gil K M
Gynecologic Oncology
2006
2006-10
Journal Article
<a href="http://doi.org/10.1016/j.ygyno.2006.01.059" target="_blank" rel="noreferrer noopener">10.1016/j.ygyno.2006.01.059</a>
The impact of obesity and age on quality of life in gynecologic surgery
adults; anemic cancer-patients; body-mass index; complications; Elderly; endometrial cancer; epoetin-alpha; gynecologic surgery; life; morbidity; obesity; Obstetrics & Gynecology; population; quality of; sf-36; trial; validation
Objective: This study was undertaken to prospectively evaluate the effect of early stage endometrial cancer, age, and obesity on quality of life (QOL). Study design: Women undergoing surgery for endometrial cancer or an adnexal mass determined at surgery to be benign (controls) were enrolled preoperatively and followed for 6 months. Results: Seventy-nine women completed the study. Functional Assessment of Cancer Therapy (FACT-G) scores increased significantly in all women; however, significant differences by patient weight and age were obtained. Obesity was associated with decreased physical FACT-G and SF-36 scores. Older women had lower SF-36 physical scores, higher emotional scores, and less change over time. Conclusion: Women with early endometrial cancer had similar changes in QOL as those who received surgery for benign disease. Obese and elderly women had domain alterations. Given the aging population and rising incidence of obesity, these results emphasize the need for QOL interventions in postoperative gynecologic care of these patients. (C) 2005 Mosby, Inc. All rights reserved.
Von Gruenigen V E; Gil K M; Frasure H E; Jenison E L; Hopkins M P
American Journal of Obstetrics and Gynecology
2005
2005-10
Journal Article
<a href="http://doi.org/10.1016/j.ajog.2005.03.038" target="_blank" rel="noreferrer noopener">10.1016/j.ajog.2005.03.038</a>
Geriatric assessment and tolerance to chemotherapy in elderly women with ovarian, primary peritoneal or fallopian tube cancer: A Gynecologic Oncology Group study
Obstetrics & Gynecology; Oncology
Von Gruenigen V E; Huang H; Tew W; Hurria A H; Lankes H; DiSilvestro P A; Mannel R S; Beumer J H; Heugel A; Herzog T J
Gynecologic Oncology
2014
2014-08
Journal Article
<a href="http://doi.org/10.1016/j.ygyno.2014.07.080" target="_blank" rel="noreferrer noopener">10.1016/j.ygyno.2014.07.080</a>
A Comparison of Quality-of-Life Domains and Clinical Factors in Ovarian Cancer Patients: A Gynecologic Oncology Group Study
carcinoma; chemotherapy; cytoreduction; functional assessment; General & Internal Medicine; Health Care Sciences & Services; intraperitoneal; Neurosciences & Neurology; ovarian-cancer; quality-of-life; scale; scores; therapy; trials
Context. Women diagnosed with ovarian cancer are at risk for reduced quality of life (QOL). It is imperative to further define these declines to interpret treatment outcomes and design appropriate clinical interventions. Objectives. The primary objective of this study was to compare data obtained from ovarian cancer patients with normative data to assess the degree to which QOL differs from the norm. Secondary objectives were to examine demographic variables and determine if there was a correlation between physical/functional and social/emotional scores during chemotherapy. Methods. Patients with Stage III/IV ovarian cancer on Gynecologic Oncology Group Protocols 152 and 172 who underwent surgery followed by intravenous paclitaxel and cisplatin completed the Functional Assessment of Cancer Therapy-Ovarian. The Functional Assessment of Cancer Therapy scale includes the four domains of physical, functional, social, and emotional well-being (PWB, FWB, SWB, and EWB, respectively). Results. Ovarian cancer patients had a total QOL (Functional Assessment of Cancer Therapy-General) score similar to the U.S. female adult population. However, the reported subscale scores were 2.0 points (95% confidence interval [Cl] 1.4-2.5, P< 0.001, effect size = 0.37) lower in PWB, 0.9 points (95% CI 0.3-1.5, P= 0.005, effect size = 0.13) lower in FWB, 5.0 points (95% CI 4.6-5.3, P< 0.001, effect size = 0.74) higher in SWB, and 0.8 points (95% CI 0.3-1.2, P< 0.001, effect size = 0.16) lower in EWB. Correlation between the sum of PWB and FWB and the sum of SWB and EWB was r= 0.53 (P< 0.001). Age was positively correlated with EWB (r= 0.193; 95% CI 0.09-0.29). Conclusion. Ovarian cancer patients have decreased QOL in physical, functional, and emotional domains; however, they may compensate with increased social support. At the time of diagnosis and treatment, patients' QOL is affected by inherent characteristics. Assessment of treatment outcomes should take into account the effect of these independent variables. J Pain Symptom Manage 2010;39:839-846. (C) 2010 US. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved
Von Gruenigen V E; Huang H Q; Gil K M; Gibbons H E; Monk B J; Rose P G; Armstrong D K; Cella D; Wenzel L
Journal of Pain and Symptom Management
2010
2010-05
Journal Article
<a href="http://doi.org/10.1016/j.jpainsymman.2009.09.022" target="_blank" rel="noreferrer noopener">10.1016/j.jpainsymman.2009.09.022</a>
A comparison of complementary and alternative medicine use by gynecology and gynecologic oncology patients
cancer patients; complementary and alternative medicines; gynecological oncology; gynecology; Obstetrics & Gynecology; Oncology; prevalence; therapies; united-states
Our objective was to describe and compare the use of complementary and alternative medicine (CAM) in gynecology and gynecological oncology patients. Five hundred and twenty-nine gynecology and gynecological oncology patients completed a questionnaire regarding: CAM use. Overall, 56.3% of gynecology and gynecological oncology patients reported current use of CAM. Therapies used included nutritional supplements (20%), prayer as medical therapy (17%), exercise as medical therapy (12%), megavitamins (10%), and green tea (10%). While 69.5% believed CAM to be beneficial, only 31.6% discussed these therapies with their physician. The women spent a mean of $656.22 on CAM (range $0-$7,000), with 31.7% receiving some insurance reimbursement. Gynecologic oncology patients (n=161) used CAM significantly more than gynecology patients (n=368) (66% vs. 52%, 95% CI=0.046-0.230, P=0.004). Gynecological oncology patients also spent more for CAM, with a mean expenditure of $711 versus $622 by gynecology patients. Within the gynecological oncology patient group, there were 69 patients currently receiving modern medical treatments for cancer; among these patients, 58% reported using CAM; of these, 39.3% communicated their use of CAM to their physician. Patients in this group spent an average of $1,178 on CAM during their illness, with only 6.3% receiving insurance reimbursement. Benefits from CAM were perceived by 54.5% in this group. We concluded that cancer patients have a higher usage rate and expenditure for CAM, particularly while they are receiving medical therapy, and are more likely to discuss the use of alternative therapies with their physicians. CAM was perceived as helpful by patients despite the lack of scientific data about its effect.
Von Gruenigen V E; White L J; Kirven M S; Showalter A L; Hopkins M P; Jenison E L
International Journal of Gynecological Cancer
2001
2001-05
Journal Article
<a href="http://doi.org/10.1046/j.1525-1438.2001.01011.x" target="_blank" rel="noreferrer noopener">10.1046/j.1525-1438.2001.01011.x</a>
Clinical disease course during the last year in ovarian cancer
carcinoma; chemotherapy; cytoreductive surgery; disease course; end; end-of-life; gynecologic cancer; Obstetrics & Gynecology; obstruction; of-life care; Oncology; ovarian-cancer; palliate; prognostic-factors; survival
Objective(s). The objective was to determine whether there were changes in the pattern and nature of hospitalizations during the last year that could be used in the assessment of whether chemotherapy should be continued. Methods. Retrospective data were collected from patients who died from ovarian cancer between 1/2000 and 12/2001. Charts from four hospitals were reviewed to abstract chemotherapy, reason for hospitalization, and the incidence of three significant clinical events (bowel obstruction, pleural effusion requiring thoracentesis, and abdominal ascites requiring paracentesis). Data were analyzed in 3-month intervals. Results. Sixty-two patient charts were reviewed. Quarterly admissions increased linearly over the year (7, 18, 27, and 47, P < 0.0001). Hospitalizations for ascites, bowel obstruction, and pleural effusion began increasing around 6 months preceding death. Twenty-two patients did not receive chemotherapy during the last 3 months. Of the 40 patients receiving chemotherapy in the last 3 months, over half were not hospitalized during the period 4-6 months before death, and a further 20% were hospitalized for nonsignificant clinical events. Approximately one-quarter of the patients, however, continued to receive chemotherapy following hospitalization for a significant clinical event. Conclusion(s). There were significant changes in the pattern and nature of hospitalization during the last 6 months that included hospitalizations for bowel obstruction, pleural effusion, or ascites. The occurrence of these events suggests that further chemotherapy should be realistically evaluated with the patient, which may reduce the number of patients who receive chemotherapy during their last few months of life. (C) 2003 Elsevier Inc. All rights reserved.
Von Gruenigen V E; Frasure H E; Reidy A M; Gil K M
Gynecologic Oncology
2003
2003-09
Journal Article
<a href="http://doi.org/10.1016/s0090-8258(03)00418-9" target="_blank" rel="noreferrer noopener">10.1016/s0090-8258(03)00418-9</a>
A case of chronic paclitaxel administration in ovarian cancer
carcinoma; chronic therapy; cisplatin; cycles; cyclophosphamide; follow-up; free survival; gynecologic malignancies; Obstetrics & Gynecology; Oncology; ovarian-cancer; paclitaxel; phase-ii trial; platinum-based chemotherapy; single-agent paclitaxel
Background. Treatment with chemotherapeutic agents, after initial ovarian tumor debulking, and during recurrence, results in extended chemotherapy. When ovarian cancer recurs, chemotherapy is continued when patients respond to therapy. However, the disease may become stable. Stable disease is clinically relevant and no longer an indication of treatment failure. Case. A woman with advanced ovarian cancer was treated with cytoxan and cisplatin chemotherapy after having surgical cytoreduction. She progressed and was placed on monthly intravenous paclitaxel. After an initial partial response to therapy, she then went into a prolonged stable course of her disease. She subsequently received 67 cycles of monthly paclitaxel therapy. Conclusion. Chronic administration of paclitaxel resulted in prolonged stabilization of disease and was well tolerated. (C) 2003 Elsevier Science (USA). All rights reserved.
Von Gruenigen V E; Karlen J R; Waggoner S E
Gynecologic Oncology
2003
2003-06
Journal Article
<a href="http://doi.org/10.1016/s0090-8258(03)00145-8" target="_blank" rel="noreferrer noopener">10.1016/s0090-8258(03)00145-8</a>
Assessment of Factors That Contribute to Decreased Quality of Life in Gynecologic Oncology Group Ovarian Cancer Trials
carcinoma; chemotherapy; clinical interventions; cytoreduction; fatigue; functional assessment; Functional Assessment of Cancer Therapy; intervention; intraperitoneal; Oncology; psychosocial support; quality-of-life domains; survivors; symptom management
BACKGROUND: The objective of this study was to assess which quality-of-life (QOL) line items on the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) were associated with low QOL in women who were receiving chemotherapy for ovarian cancer. METHODS: Patients with stage III or IV ovarian cancer on Gynecologic Oncology Group Protocols 152 and 172 who underwent primary surgery followed by intravenous paclitaxel and cisplatin completed the FACT-O. The FACT scale includes the 4 domains of physical, functional, social, and emotional well being (PWB, FWB, SWB, EWB, respectively). Women who had overall FACT-O scores in the lowest quartile (01) were compared with women in the upper 3 quartiles (Q2-Q4). The proportions of women in each group that selected the 2 worst categories for each item were compared. The level of significance was set at P < .005. RESULTS: Before Cycle 4, 361 patients (86.4%) provided valid QOL assessments. For PWB, a significantly greater proportion of women in 01 versus Q2 through 04 selected the 2 worst categories of several physical symptoms (nausea, pain, feeling ill, and being bothered by the side effects of treatment). For FWB, significant differences included being able to work, being content with the quality of their life, and sleeping well. For EWB, there were significant differences in feeling nervous and worrying about dying. There were virtually no differences between groups in SWB. Low interest in sex was reported by 56% to 88% of all patients (Q1-Q4). CONCLUSIONS: A large proportion of women with FACT-O scores in the lowest quartile reported problems that potentially were amenable to clinical interventions, such as symptom management and psychosocial support. Cancer 2009;115:4857-64. (C) 2009 American Cancer Society.
Von Gruenigen V E; Huang H Q; Gil K M; Gibbons H E; Monk B J; Rose P G; Armstrong D K; Cella D; Wenzel L
Cancer
2009
2009-10
Journal Article
<a href="http://doi.org/10.1002/cncr.24520" target="_blank" rel="noreferrer noopener">10.1002/cncr.24520</a>
Rodent models for ovarian cancer research
animal models; carcinoma cell-line; epithelial; gene-therapy; immunodeficient mice; luteinizing-hormone; lysophosphatidic acid; metastasis in-vivo; mouse models; neoplasms; nude-mice; Obstetrics & Gynecology; Oncology; ovarian-cancer; p53; review; tumor-associated antigens
Animal models that are biologically and clinically relevant are essential for conducting research to investigate the pathophysiologic progression of disease and to develop diagnostic or therapeutic strategies. Several rodent models that vary in methods of induction allow appropriate in vivo evaluation for ovarian cancer. The types of rodent models discussed include chemically (nonhormonal and hormonal) induced, genetic (knockout and transgenic), xenograft, and syngeneic. A summary of the available rodent models is provided with a discussion of the advantages and disadvantages of each. Optimization and application of these rodent models to future research may benefit the detection and treatment of ovarian cancer.
Stakleff K D S; Von Gruenigen V E
International Journal of Gynecological Cancer
2003
2003-07
Journal Article
<a href="http://doi.org/10.1046/j.1525-1438.2003.13317.x" target="_blank" rel="noreferrer noopener">10.1046/j.1525-1438.2003.13317.x</a>
A novel early-stage orthotopic model for ovarian cancer in the Fischer 344 rat
animal-model; epithelial neoplasms; Fischer 344 rats; gene-therapy; guinea-pigs; hormone; induction; mice; mouse model; Obstetrics & Gynecology; Oncology; orthotopic; ovarian-cancer; stimulation; tumors
The purpose of our study was to ascertain the progression of metastases in a novel ovarian cancer model designed to mimic early-stage disease by utilizing an orthotopic injection technique. Female Fischer 344 rats were injected with either 10(4) or 10(5) NuTu-19 cells by intraperitoneal or orthotopic injection. Peritoneal washings and histologic specimens were examined to correlate the incidence and extent of tumor growth. In a second phase, orthotopic injections of 10(2) and 10(3) cells were compared to that of 10(4) cells. Progression of ovarian cancer was observed by gross and microscopic examinations in both intraperitoneal and orthotopic models. Pelvic extension and abdominal adhesions uniquely characterized the orthotopically injected animals. Numbers of identifiable metastases declined with lower cell inocula, confirming that early-stage disease was extended to at least 14 days with 10(2) NuTu-19 cells. The orthotopic ovarian cancer model emulates early disease with the initiation of a primary tumor that is localized within the inherent microenvironment. The orthotopic model offers a clinically relevant alternative for future cancer research that allows for the investigation of therapeutic strategies against early stages of the disease process.
Stakleff K D S; Rouse A G; Ryan A P; Haller N A; Von Gruenigen V E
International Journal of Gynecological Cancer
2005
2005-03
Journal Article
<a href="http://doi.org/10.1136/ijgc-00009577-200503000-00010" target="_blank" rel="noreferrer noopener">10.1136/ijgc-00009577-200503000-00010</a>
Diet and ovarian cancer: impact on prevention and survival.
Adult; Female; Diet; Antineoplastic; Dietary Fats – Adverse Effects; Milk – Adverse Effects; Ovarian Neoplasms – Prevention and Control; Ovarian Neoplasms – Therapy; Vegetables – Therapeutic Use
Gil K M; von Gruenigen V E
Oncology Nutrition Connection
2004
2004
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
[Commentary on] Use of complementary and alternative medicine among women with gynecologic cancers.
Female; United States; Prevalence; Outpatients; Genital Neoplasms; Female – Therapy; Alternative Therapies – Utilization
von Gruenigen V E
Women's Oncology Review
2002
2002-06
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Complementary and alternative medicine use in the Amish.
Adult; Female; Ohio; Self Report; Human; Surveys; Amish; Alternative Therapies – Utilization
Objective: To examine the rate of utilization of complementary and alternative medicine (CAM) in Amish women, a population that traditionally uses non-mainstream medicine. Methods & Results: Sixty-six Amish women completed a survey concerning their use of CAM. Thirty-six percent of the Amish women used at least one form of CAM, primarily reporting a use of diet and nutrition programs, herbal therapies, and chiropractic medicine. In addition, ten pregnant Amish women reported using echinacea, St. John's Wort, red clover, garlic and ginseng. Conclusion: This survey highlights the need to address potential adverse effects of herbal therapies in young women who are a member of a group that may use non-mainstream medicine. Copyright © 2002 by Elsevier Science (USA).
von Gruenigen V E; Showalter A L; Gil K M; Frasure H E; Hopkins M P; Jenison E L
Complementary Therapies in Medicine
2001
2001-12
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1054/ctim.2001.0485" target="_blank" rel="noreferrer noopener">10.1054/ctim.2001.0485</a>
[Commentary on] Predictors of complications after inguinal lymphadenectomy.
Female; Groin – Surgery; Lymphedema – Etiology; Postoperative Complications – Risk Factors; Vaginal Neoplasms – Complications; Vaginal Neoplasms – Surgery
von Gruenigen V E
Women's Oncology Review
2001
2001-12
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
[Commentary on] Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy.
Female; Sensitivity and Specificity; Tomography; Laparotomy; Emission-Computed; Ovarian Neoplasms – Diagnosis; Peritoneal Neoplasms – Diagnosis
von Gruenigen V E
Women's Oncology Review
2002
2002-03
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
[Commentary on] Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93)
Female; Quality of Life; Disease Progression; Outpatients; Drug Therapy; Combination; Carboplatin; Carcinoma – Drug Therapy; Ovarian Neoplasms – Drug Therapy; Paclitaxel – Therapeutic Use
von Gruenigen V E
Women's Oncology Review
2001
2001-06
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Obesity-related endometrial cancer: an update on survivorship approaches to reducing cardiovascular death.
Behavior; Body Mass Index; Cardiovascular Diseases – Etiology; Cardiovascular Diseases – Mortality; Cardiovascular Diseases – Prevention and Control; Cardiovascular Diseases/etiology/*mortality/prevention & control; Comorbidity; Endometrial cancer; Endometrial Neoplasms – Etiology; Endometrial Neoplasms – Mortality; Endometrial Neoplasms/etiology/*mortality; Female; Humans; lifestyle; obesity; Obesity – Complications; Obesity – Mortality; Obesity/complications/*mortality; Risk Factors; Risk Reduction Behavior; Survivors – Psychosocial Factors; Survivors/*psychology; survivorship
As the rate of obesity increases worldwide, so will the number of women diagnosed with obesity-related malignancy. The strongest correlation between obesity and cancer is endometrial cancer (EC). Obesity is the most significant modifiable risk factor for development of EC and also contributes to the most common cause of death in EC survivors-cardiovascular disease (CVD). Most cancer survivors after diagnosis do not implement lifestyle changes aimed at weight-loss and CVD risk reduction. This selective review highlights recent novel and unique approaches for managing CVD co-morbidities in EC survivorship.
Laskey R A; McCarroll M L; von Gruenigen V E
BJOG : an international journal of obstetrics and gynaecology
2016
2016-01
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1111/1471-0528.13684" target="_blank" rel="noreferrer noopener">10.1111/1471-0528.13684</a>
Complementary and alternative medicine use in the Amish.
*Christianity; Adult; Complementary Therapies/*statistics & numerical data; Female; Humans; Ohio; Phytotherapy/statistics & numerical data; Plant Preparations/therapeutic use; Pregnancy; Pregnancy Complications/therapy
OBJECTIVE: To examine the rate of utilization of complementary and alternative medicine (CAM) in Amish women, a population that traditionally uses non-mainstream medicine. METHODS & RESULTS: Sixty-six Amish women completed a survey concerning their use of CAM. Thirty-six percent of the Amish women used at least one form of CAM, primarily reporting a use of diet and nutrition programs, herbal therapies, and chiropractic medicine. In addition, ten pregnant Amish women reported using echinacea, St. John's Wort, red clover, garlic and ginseng. CONCLUSION: This survey highlights the need to address potential adverse effects of herbal therapies in young women who are a member of a group that may use non-mainstream medicine.
von Gruenigen V E; Showalter A L; Gil K M; Frasure H E; Hopkins M P; Jenison E L
Complementary Therapies in Medicine
2001
2001-12
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1054/ctim.2001.0485" target="_blank" rel="noreferrer noopener">10.1054/ctim.2001.0485</a>
The effect of intermittent-release intraperitoneal chemotherapy on wound healing.
Animals; Antineoplastic Agents/administration & dosage/*pharmacology; Carboplatin/administration & dosage/*pharmacology; Infusions; Laparotomy; Male; Paclitaxel/administration & dosage/*pharmacology; Parenteral; Rats; Sprague-Dawley; Tissue Adhesions/chemically induced; Wound Healing/*drug effects
OBJECTIVE: Our purpose was to study the effect on wound healing when intraperitoneal chemotherapy was instilled on a daily basis. STUDY DESIGN: Intraperitoneal carboplatin, Taxol, or saline solution was instilled daily into 70 rats after they underwent laparotomy. The animals were killed and analyzed for adhesions. An area measuring 5 x 5 cm including the incision was also harvested for biomechanical testing. The wound thickness was measured, and the Shore Western Materials Testing System (Monrovia, Calif.) was used to test the force required to break the wound, the stress, and the stiffness. RESULTS: Groups of 10 rats received saline solution control, carboplatin 6 mg/kg, 7 mg/kg, 8 mg/kg, or Taxol 2.5 mg/kg, 3.0 mg/kg, or 3.5 mg/kg. The total dose was divided into seven equal amounts, administered daily. No significant adhesions developed in any of the animals. The carboplatin group experienced no significant decrease in wound thickness whereas the higher-dose Taxol group had a significant decrease in thickness from 1.06 mm to 0.72 mm (p = 0.02). The wound-breaking strength (force) also decreased for the highest-dose Taxol group from 710 gm to 411 gm (p = 0.02). The wound stiffness was also decreased from 69 gm/mm to 46 gm/mm (p = 0.01). The other measured parameters for both the Taxol and carboplatin groups were not significantly decreased when compared with those of controls. CONCLUSION: The immediate instillation of divided daily carboplatin did not influence wound strength whereas the use of Taxol on a similar schedule significantly decreased wound strength.
Hopkins M P; von Gruenigen V E; Holda S; Weber B
American journal of obstetrics and gynecology
1997
1997-04
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1016/s0002-9378(97)70606-9" target="_blank" rel="noreferrer noopener">10.1016/s0002-9378(97)70606-9</a>
Reply
von Gruenigen V E; Hopkins
Gynecologic oncology
2000
2000-11
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1006/gyno.2000.5988" target="_blank" rel="noreferrer noopener">10.1006/gyno.2000.5988</a>
Alternative medicine in gynecologic oncology: A case report.
*Complementary Therapies; Carcinoma; Diarrhea/*etiology; Female; Fever/*etiology; Hospitalization; Humans; Medical History Taking; Medicinal/*adverse effects; Middle Aged; Neutropenia/*etiology; Plants; Squamous Cell/drug therapy/*radiotherapy; Time Factors; Uterine Cervical Neoplasms/drug therapy/*radiotherapy
A patient with Stage IIB squamous cell cancer of the cervix presented 10 days into her primary radiation therapy with neutropenic fever and diarrhea requiring hospitalization and delay in treatment. The patient's history revealed extensive use of alternative therapies including potential toxic botanicals. This case raises the possibility that a patient's use of alternative therapies may have caused toxicity and delayed primary therapy. Gynecologic oncology patients may be using alternative therapies justifying the need for incorporating this classification into the historical exam.
von Gruenigen V E; Hopkins M P
Gynecologic oncology
2000
2000-04
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1006/gyno.2000.5743" target="_blank" rel="noreferrer noopener">10.1006/gyno.2000.5743</a>